Sermorelin vs CJC-1295: Which GHRH Analog for Your Research?

Sermorelin and CJC-1295 are the two most widely used GHRH (growth hormone-releasing hormone) analogs in peptide research, and choosing between them is one of the most common decisions researchers face when designing GH-axis studies. Both activate the same receptor (the GHRH receptor on anterior pituitary somatotrophs) and both stimulate growth hormone release — but they differ meaningfully in molecular stability, pharmacokinetic profiles, and practical research applications. Understanding these differences is essential for selecting the optimal GHRH analog for your specific experimental design.

This guide provides a detailed side-by-side comparison of Sermorelin and CJC-1295 No DAC (Mod GRF 1-29), covering their molecular structures, enzymatic stability, GH release kinetics, published data, and how each performs in combination protocols with GH secretagogues like Ipamorelin. We also include Tesamorelin in the comparison for researchers considering the full GHRH analog landscape. For a complete overview of CJC-1295 specifically, including the DAC vs No DAC distinction, see our CJC-1295 Research Guide.

The Molecular Foundation: What Both Compounds Share

Both Sermorelin and CJC-1295 are synthetic analogs of the same parent molecule: human growth hormone-releasing hormone (GHRH). Native GHRH is a 44-amino acid hypothalamic peptide that travels via the hypothalamic-hypophyseal portal system to the anterior pituitary, where it binds the GHRH receptor on somatotroph cells and stimulates GH synthesis and release. Both Sermorelin and CJC-1295 target this same GHRH receptor and trigger the same intracellular signaling cascade: Gαs → adenylate cyclase → cAMP → PKA → GH gene transcription and granule exocytosis.

The critical challenge with native GHRH is its extremely short circulating half-life — approximately 7-10 minutes — due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), which cleaves the N-terminal dipeptide and inactivates the molecule. Sermorelin and CJC-1295 represent two different solutions to this stability problem, and understanding these different solutions explains their different pharmacokinetic profiles.

Sermorelin: The Minimal GHRH Analog

Molecular Identity

• Full Name: Sermorelin Acetate / GRF 1-29 NH2 (GHRH 1-29)
• CAS Registry Number: 86168-78-7
• Molecular Weight: 3,357.88 g/mol
• Amino Acid Count: 29 residues
• Structure: First 29 amino acids of native GHRH(1-44), with C-terminal amidation
• DPP-4 Modification: None — retains native N-terminal sequence
• Effective Half-Life: ~10-15 minutes
• FDA Status: Approved as Geref for GH deficiency diagnosis

Sermorelin represents the minimally modified approach to GHRH analog design. Research demonstrated that the first 29 amino acids of native GHRH retain full biological activity — residues 30-44 contribute to stability but are not required for receptor binding or activation. Sermorelin is therefore GHRH(1-29) with a C-terminal amide for improved stability, but with no modifications to the N-terminal region that is vulnerable to DPP-4 cleavage. This means Sermorelin retains the same DPP-4 vulnerability as native GHRH, resulting in a short half-life of approximately 10-15 minutes — slightly longer than native GHRH but still quite brief.

Key Advantage: Regulatory Pedigree

Sermorelin’s primary advantage is its regulatory history. As an FDA-approved diagnostic agent (Geref), it has the most extensive human safety dataset of any GHRH analog, with published clinical trial data spanning decades. This regulatory pedigree makes it the GHRH analog with the most established safety profile for translational research contexts.

CJC-1295 No DAC (Mod GRF 1-29): The Stabilized GHRH Analog

Molecular Identity

• Full Name: CJC-1295 without DAC / Modified GRF (1-29) / Mod GRF 1-29
• CAS Registry Number: 863288-34-0
• Molecular Weight: ~3,367.97 g/mol
• Amino Acid Count: 29 residues (with modifications)
• Structure: GHRH(1-29) with amino acid substitutions at positions 2, 8, 15, and 27
• DPP-4 Modification: Yes — D-Ala substitution at position 2 confers DPP-4 resistance
• Effective Half-Life: ~30 minutes
• FDA Status: Not approved — research chemical

CJC-1295 No DAC represents the engineered approach to GHRH stabilization. It retains the GHRH(1-29) core but introduces four key amino acid substitutions designed to resist enzymatic degradation. The most critical substitution is at position 2, where the native alanine is replaced with D-alanine — a stereoisomeric inversion that renders the N-terminal dipeptide bond resistant to DPP-4 cleavage. Additional substitutions at positions 8, 15, and 27 further protect against other circulating peptidases. The net result is approximately a doubling of effective half-life compared to Sermorelin (from ~15 minutes to ~30 minutes), providing a more sustained GHRH receptor stimulation window. Published pharmacokinetic characterization was documented by Teichman et al. (2006) in the Journal of Clinical Endocrinology & Metabolism.

Head-to-Head Comparison: Sermorelin vs CJC-1295

• DPP-4 Resistance: Sermorelin has none — retains native susceptibility to DPP-4 degradation. CJC-1295 has strong DPP-4 resistance via D-Ala substitution at position 2, plus additional peptidase resistance from modifications at positions 8, 15, and 27.
• Effective Half-Life: Sermorelin is approximately 10-15 minutes. CJC-1295 is approximately 30 minutes — roughly double the active window.
• GH Release Intensity Per Dose: CJC-1295’s longer receptor occupancy produces a more sustained GH pulse. Sermorelin’s shorter occupancy produces a sharper but briefer GH spike. Published comparative data suggests CJC-1295 produces greater total GH release (AUC) per administration event.
• Physiological Mimicry: Sermorelin’s shorter action more closely mimics the brief, physiological GHRH pulses from the hypothalamus. CJC-1295’s extended window, while still pulsatile, produces a somewhat wider GH pulse than occurs naturally.
• Regulatory Data: Sermorelin has the clear advantage — FDA-approved with decades of published safety data. CJC-1295 has published pharmacokinetic data but has not undergone the same regulatory review process.
• Research Frequency: Due to its shorter half-life, Sermorelin protocols typically require more frequent administration than CJC-1295 to achieve equivalent total GHRH receptor stimulation over time.
• Cost per Effective Dose: CJC-1295’s improved stability means more of each dose reaches the pituitary in active form, potentially providing better value per milligram for research applications where total GH stimulation is the objective.

Combination Research with Ipamorelin

Both Sermorelin and CJC-1295 are frequently studied in combination with Ipamorelin (a selective GH secretagogue), because GHRH analogs and ghrelin receptor agonists target complementary pathways on the same pituitary somatotroph cell. The question of which GHRH analog to pair with Ipamorelin depends on your research priorities:

Sermorelin + Ipamorelin

This combination produces the most physiologically natural GH pulsatility because both compounds have short half-lives (Sermorelin ~15 min, Ipamorelin ~30 min), creating a sharp, synchronized GH spike that closely mimics the timing of endogenous GHRH/ghrelin pulsatile signaling. Best for research examining physiological GH pulse dynamics and their downstream tissue effects.

CJC-1295 No DAC + Ipamorelin

This combination, available as a pre-blended product from Apex Laboratory (CJC-1295 + Ipamorelin Blend), produces a slightly wider GH pulse with greater total GH release per event because CJC-1295’s longer receptor occupancy extends the stimulation window. This is the more commonly used research combination for protocols where maximizing GH output is the primary objective. For complete details on the combination mechanism, see our Ipamorelin Research Guide.

Where Does Tesamorelin Fit?

Tesamorelin (CAS: 218949-48-5, MW: 5,135 g/mol) is the third major GHRH analog and offers a distinct profile from both Sermorelin and CJC-1295. It is the full-length GHRH(1-44) with a trans-3-hexenoic acid N-terminal modification for enhanced stability. Key distinguishing characteristics include its larger size (full 44 amino acids vs 29 for the others), its FDA approval as Egrifta for HIV-associated lipodystrophy (giving it the strongest regulatory and clinical data package of any GHRH analog for a metabolic indication), and its published clinical trial data from NEJM and JAMA documenting body composition effects. Researchers studying GHRH analogs in metabolic contexts often include Tesamorelin as a comparator because of this unique clinical dataset.

Choosing Your GHRH Analog: Decision Framework

Use Sermorelin when your research requires the most physiologically natural GHRH signaling, when regulatory pedigree and published human safety data are important for your experimental context, or when studying the baseline properties of GHRH receptor activation without the confound of modified amino acid substitutions.

Use CJC-1295 No DAC when maximizing GH stimulation per dose is the priority, when DPP-4 degradation is a concern in your experimental system, or when combining with Ipamorelin in a dual-pathway protocol for maximum GH output.

Use Tesamorelin when your research focuses on metabolic/body composition endpoints and you need a GHRH analog with published clinical data in metabolic contexts, or when studying full-length GHRH pharmacology rather than the truncated 1-29 fragment.

Storage, Handling, and Reconstitution (All Three Compounds)

Lyophilized Storage

Store all three at -20°C. All are medium-sized peptides (3,300-5,100 g/mol) with good lyophilized stability for 12-18+ months. See our Peptide Storage Guide.

Reconstitution

All dissolve readily in bacteriostatic water. For 2 mg vials, adding 2 mL produces 1 mg/mL (1,000 mcg/mL). Use our reconstitution calculator or follow our reconstitution protocol.

After Reconstitution

Store at 2-8°C. Sermorelin: use within 14 days. CJC-1295 No DAC: use within 14 days. Tesamorelin: use within 14 days. Aliquot for -20°C frozen storage.

Frequently Asked Questions

Which is stronger, Sermorelin or CJC-1295?

CJC-1295 No DAC produces greater total GH release per dose due to its extended half-life (~30 min vs ~15 min for Sermorelin). Its DPP-4 resistant modifications mean a higher percentage of each administered dose reaches the pituitary in active form. However, “stronger” depends on context — Sermorelin’s shorter, more physiological GH pulse may be preferable for research examining natural GH pulsatility dynamics.

Can I use Sermorelin and CJC-1295 together?

This is not a standard research combination because both compounds target the same receptor (GHRH receptor). Combining two GHRH analogs provides receptor redundancy rather than complementary pathway stimulation. The more productive combination approach is pairing one GHRH analog (either Sermorelin or CJC-1295) with a GH secretagogue like Ipamorelin that targets the complementary ghrelin receptor pathway.

What is the difference between CJC-1295 and Mod GRF 1-29?

CJC-1295 without DAC and Mod GRF 1-29 (Modified GRF 1-29) are the same compound — different names for the GHRH(1-29) analog with DPP-4 resistant amino acid substitutions. For the full explanation including the DAC version, see our CJC-1295 Research Guide.

Is Sermorelin FDA-approved?

Yes. Sermorelin acetate is FDA-approved as Geref (GRF) for the diagnostic evaluation of pituitary GH secretion. This approval was based on clinical trial data demonstrating its ability to stimulate GH release as a diagnostic provocation test. However, the research-grade Sermorelin sold by Apex Laboratory is intended for in-vitro laboratory research, not diagnostic or therapeutic use.

Which GHRH analog pairs best with Ipamorelin?

CJC-1295 No DAC is the most commonly used GHRH analog in combination with Ipamorelin because its ~30-minute half-life provides a sustained stimulation window that overlaps well with Ipamorelin’s activity duration. Apex Laboratory offers a pre-blended CJC-1295 + Ipamorelin Blend for this standard research combination.

Continue Your Research

• Ipamorelin Research Guide: The Selective Growth Hormone Secretagogue
• CJC-1295 Research Guide: With DAC vs Without DAC Explained
• AOD9604 Research Guide: The hGH Fragment for Metabolic Research
• Retatrutide: The Triple Agonist Peptide

Research Use Disclaimer

This article is provided for educational and research reference purposes only. Sermorelin, CJC-1295, Tesamorelin, and all products sold by Apex Laboratory are intended exclusively for in-vitro laboratory research use and are not for human consumption. Researchers should consult the published pharmacokinetic literature cited in this article for complete data.